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Abstract  
Objective: To investigate the association between abacavir (ABC) use and recurrent 
myocardial infarction (MI) among HIV-positive people with a prior MI. 
Design: International multi-cohort collaboration with follow-up from 1999-2016. 
Methods: The rate of recurrent MI was described among D:A:D participants who 
experienced an index MI whilst in the study, and who remained under follow-up beyond 
28 days after this MI.  Follow-up was considered to the date of next MI, death, 
01/Feb/2016 or 6 months after last clinic visit.  Poisson regression models considered 
associations between recurrent MI and exposure to ABC (use at index MI, current post-
MI exposure and cumulative exposure), before and after adjusting for calendar year. 
Results:  The 984 individuals who experienced an index MI during the study (91.3% 
male, median age 51 at index MI) were followed for 5312 person-years (PY) over which 
time there were 136 recurrent MIs (rate 2.56/100 PY, 95% Confidence Interval 2.13-
2.99). Rates were 2.40 (1.71-3.09) and 2.65 (2.10-3.21)/100 PY in those who were and 
were not on ABC, respectively, at the index MI, and 2.90 (2.01-3.78) and 2.44 (1.95-
2.93)/100 PY in those who were and were not currently receiving ABC, respectively, 
post-MI.  No association was seen with recurrent MI and either cumulative exposure to 
ABC (RR=0.86 [0.68-1.10]/5 years), receipt of ABC at index MI (0.90 [0.63-1.29]) nor 
recent post-MI exposure to ABC (1.19 [0.82-1.71]). 
Conclusions: Among people with a previous MI, there was no evidence for an 
association between use of ABC post-MI and an elevated risk of a recurrent MI.   
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 INTRODUCTION 
Since the initial presentation of findings from the Data Collection on Adverse Events of 
Anti-HIV Drugs (D:A:D) Study in early 2008 demonstrating a 90% increase in the risk of 
myocardial infarction (MI) in HIV-positive individuals receiving antiretroviral therapy 
(ART) regimens that included abacavir (ABC) [1], other studies have reported 
inconsistent findings [2-5].  A recent updated analysis from the D:A:D study, that 
included follow-up and events from 2008 onwards, reported that the relative hazard (RR) 
for MI associated with recent ABC use in the post-2008 period was unchanged from that 
previously reported [6]. These findings, in the context of demonstrated changes in the 
characteristics of those receiving ABC-based regimens, suggested that the association 
was unlikely to be explained by a higher underlying risk of MI in ABC-treated 
individuals prior to starting the drug.    
Most of the studies that have considered the association between ABC exposure and MI 
risk, including the D:A:D analyses, have focussed on populations of HIV-positive people 
in which few individuals have already experienced a prior MI. However, such individuals 
represent a very high-risk subgroup that will likely be exposed to multiple lifestyle and 
clinical interventions for secondary prevention.  We investigated the association between 
ABC use and subsequent MI risk among the patients who had already experienced an MI 
during prospective D:A:D follow-up.
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 METHODS 
Study design 
The D:A:D Study was an observational study of >49,000 HIV-1-positive patients from 11 
cohorts from Europe, Australia, and the United States [7].  The primary study aim was to 
investigate associations between the use of ART and the risk of cardiovascular disease 
(CVD) and other major disease events.  The standardised dataset, collected prospectively 
during routine clinic visits, includes information on socio-demographic factors, AIDS 
events and deaths, risk factors for CVD, laboratory markers for monitoring HIV 
(including CD4 count and HIV RNA) and CVD, ART and treatments that influence CVD 
risk.   
Information on incident MI events was reported to the study co-ordinating centre via a 
study event form which captured detailed information about the event and related 
circumstances.  Each reported event was validated and coded using criteria applied in the 
WHO MONICA Study [8], with this process being performed blind to information about 
the patient's ART status.  Reported MIs were classified as definite, possible or 
unclassifiable using standardised criteria for classification including relevant symptoms, 
relevant increase and decline in cardiac enzymes, ischemic changes in 
electrocardiographic readings and, in cases of death, autopsy results if available. Fatal MI 
events were additionally validated using information collected on the Coding of Causes 
of Death (CoDe) form [9], and all complex and/or fatal MI cases were additionally 
validated with the input of an independent cardiologist.  
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Statistical methods 
We considered the rate of recurrent MI among D:A:D participants who experienced an 
MI during study follow-up (the ‘index’ MI) and who remained alive and under follow-up 
at 28 days post-MI (to exclude any index MIs resulting in death).  Follow-up was 
considered from 28 days post-MI to the first date of next MI, death, 01/Feb/2016 or 6 
months after last clinic visit.  Sixty-four of the individuals (6.5%) had experienced an MI 
prior to D:A:D entry (and prior to the index MI); to be consistent with the main D:A:D 
analyses, we did not exclude this subgroup but sensitivity analyses (which excluded the 
subgroup) suggested that our findings were robust to their inclusion. 
Poisson regression models were used to evaluate associations between recurrent MI and 
exposure to ABC.  As in previous analyses of the dataset [5], each individual's follow-up 
was split into a series of consecutive one-month periods and his/her clinical, 
immunologic and virologic status at the start of each period was established.  Three 
different exposures to ABC were considered: i) use of ABC at the time of initial MI 
(time-fixed); ii) current, post-MI exposure (time-updated, defined as currently receiving 
ABC or having received the drug at any time in the six months leading up to the start of 
each month); and iii) cumulative exposure (time-updated, including exposure both pre- 
and post-MI and scaled to reflect a 5-year increment).  Fixed confounders considered 
were gender, ethnic group, and mode of HIV acquisition.  Time-updated covariates 
considered were calendar year, age (continuous covariate), smoking status, body mass 
index (BMI), cumulative exposure to the protease inhibitors lopinavir, indinavir and 
darunavir, and the development of dyslipidaemia, diabetes mellitus or hypertension 
(Table 1).   
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All analyses were performed using SAS version 9.3.  
 
RESULTS 
Of the 1191 participants who developed an index MI during the study, 984 remained 
under follow-up for at least 28 days and were included in the study.  These individuals 
were largely male (91.3%) and infected with HIV through sex between men (58.8%).  At 
the time of the index MI, the participants had a median age of 51 years (inter-quartile 
range [IQR] 45-59), the majority were current (55.5%) or ex- (24.3%) smokers, 14.3% 
had a family history of MI, and most had either a moderate (10-20%, 33.0%) or high 
(>20%, 27.1%) 10-year predicted Framingham risk for CVD.  The index MI had occurred 
in 1999-2001, 2002-2004, 2005-2007, 2008-2010, 2011-2013 and from 2014-2016 in 95 
(9.7%), 209 (21.2%), 207 (21.0%), 196 (19.9%), 184 (18.7%) and 93 (9.5%) of 
participants, respectively. 
The median CD4 count at index MI was 511 (IQR 348-740) cells/mm3.  At the time of 
index MI, the majority of participants (959, 97.5%) had ever received ART, with 860 
(87.4%) of patients currently receiving ART.  Two-thirds (691, 70.3%) had an HIV RNA 
<50 copies/ml. Of the 584 people who were not already receiving lipid-lowering drugs at 
the time of the index MI, 306 (52.4%) started them within the first 28 days after MI.  
Similarly, 245/763 (32.1%) of those not already receiving angiotensin converting enzyme 
(ACE) inhibitors and 330/699 (47.2%) of those not already receiving anti-hypertensives 
started these within the first 28 days post index MI.  Two-thirds of participants (63.2%) 
received an angioplasty and 44 (4.5%) received coronary artery bypass surgery in the first 
28 days post MI 
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Five hundred and three (51.2%) people had received ABC prior to their index MI for a 
median of 3.1 years (range 0-13.9) of whom 327 were still on ABC at the time of the 
index MI.  Two hundred and thirty-nine of the 327 (73.1%) stopped the drug at a median 
of 323 (range 0-5252) days after MI, with 71 of them subsequently re-starting the drug.  
Eighty of the 481 participants who had not previously received ABC prior to the index 
MI (16.6%), started the drug for the first time at a median of 1089 (range 3-4384) days 
after the index MI.  Of the 151 people who either started ABC for the first time or who 
restarted ABC after previous use, the majority (116/151) did so prior to the publication of 
the initial D:A:D study findings in 2008 [1].  
The 984 included participants were followed for a median of 4.7 (range 0.1-15.3) years 
after the index MI (total person-years (PY): 5312).  Over this time, 136 people (13.8%) 
had at least one recurrent MI (rate: 2.56/100 PY (95% confidence interval [CI] 2.13-
2.99).  Rates of recurrent MI were 2.40 (1.71-3.09, 47 events over 1959 PY) and 2.65 
(2.10-3.21, 89 events over 3353 PY)/100 PY in those who were and were not on ABC at 
the time of their index MI; rates were 2.90 (2.01-3.78, 41 events over 1415 PY) and 2.44 
(1.95-2.93, 95 events over 3897 PY)/100 PY in those who were and were not currently 
receiving ABC post-MI, respectively.  There was no significant association between 
recurrent MI and either cumulative exposure to ABC (RR 0.86 [0.68-1.10]/5 years), 
receipt of ABC at index MI (0.90 [0.63-1.29]) or current post-MI exposure (1.19 [0.82-
1.71], Table 1).  Whilst earlier calendar year, a non-sexual or injection drug use route of 
HIV acquisition and a prior diagnosis of diabetes were each associated with an increased 
risk of recurrent MI in univariate analyses (Table 1), adjustment for these factors did not 
reveal any significant associations with exposure to ABC.  
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 CONCLUSIONS 
Whilst previous study findings have suggested that current use of ABC in HIV-positive 
people is associated with an almost doubling in MI risk [1], we found no evidence that 
use of ABC was associated with an elevated risk of recurrent MI in those with a previous 
MI. Although most of the continued/new ABC use in those with an MI was in the earlier 
years of the study, when the risk of recurrent MI was higher than it is currently [10-12], 
adjustment for calendar year did not modify our findings.   
Whilst these results appear to contradict with previous findings, there are two main 
reasons why we might expect the association with ABC exposure to differ in those with a 
prior MI.  Firstly, recurrent MIs in those with an index MI are more likely to reflect the 
uptake and success of post-MI interventions to manage CVD and prevent subsequent 
cardiovascular events in this group than differences in established risk factors for a 
primary MI.  Our finding that few of the established CVD risk factors are associated with 
recurrent MI, other than diabetes, supports the existence of a different set of risk factors 
for recurrent MI, a notion which is consistent with the limited literature from the general 
population [13-15].  Secondly, one of the reasons for the continued debate about the 
potential association between ABC and MI is that there is no confirmed biological 
mechanism for the association.  Arguably, the most promising potential mechanism to 
date relates to the association reported between ABC and platelet reactivity [16-18], a 
mechanism that would be consistent with the apparent reversible nature of the ABC 
association with MI; a similar association has also recently been described with protease 
inhibitors [19].  We would, however, expect the majority of those with an MI to be 
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receiving anti-platelet therapy, more recently with the dual combination of aspirin and 
clopidogrel, which could plausibly modify any effects of ABC on platelet reactivity.  
Unfortunately, we do not collect detailed information on the clinical presentation of each 
MI or on subsequent management and are therefore unable to assess the numbers treated 
in this way to test this hypothesis.    
We note that our aim in the present study was to exclude the possibility that any of the 
established CVD risk factors may have confounded (and possibly obscured) an 
association with ABC rather than to identify risk factors for recurrent MI per se.  For this 
reason, we have not investigated above factors in more depth, or a the potential role of 
chronic kidney disease, a factor previously demonstrated to be associated with CVD risk 
in the study [20] – information on the latter was often unavailable in the earlier years of 
the study although in more recent years, ABC may have been a treatment of choice in 
people with chronic kidney disease.  Furthermore, we do not capture information on 
lifestyle/behavioural modifications, and so cannot investigate whether any changes in 
these may have modified the subsequent risk of recurrent MI and/or its association with 
continued or new ABC use.  We cannot, therefore, rule out the possibility that our 
findings may result from residual confounding due to different post-MI management 
among those who are and are not receiving ABC. 
In summary, among people with a previous MI, there was no evidence for an association 
between use of ABC post-MI and an elevated risk of a recurrent MI.   
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 Aquitaine Cohort  (France)                                                                                                                               
Composition du Conseil scientifique : 
Coordination: F. Bonnet*, F. Dabis*  
Scientific committee: M. Dupon, V. Gaborieau, D. Lacoste, D. Malvy, P. Mercié, P. 
Morlat, D. Neau,  JL. Pellegrin, S. Tchamgoué, E. Lazaro, C. Cazanave, M. 
Vandenhende, M.O. Vareil, Y. Gérard, P. Blanco, S. Bouchet, D. Breilh, H. Fleury, I. 
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Epidemiology and Methodology: F. Bonnet*, G. Chêne, F. Dabis*, R. Thiébaut, L. 
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Immunology: I. Pellegrin, P. Blanco 
Virology: H. Fleury, Me. Lafon, P. Trimoulet, P. Bellecave, C. Tumiotto 
Pharmacology: S. Bouchet, D. Breilh, F. Haramburu, G. Miremeont-Salamé 
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Data collection, Project Management and Statistical Analyses: MJ. Blaizeau, M. Decoin, 
C. Hannapier, E. Lenaud et A. Pougetoux; S. Delveaux, C. D’Ivernois, F. Diarra B. 
Uwamaliya-Nziyumvira, O. Leleux; F. Le Marec, Eloïse Boerg, S. Lawson-Ayayi;  
IT department and eCRF development: G. Palmer, V. Conte, V. Sapparrart 
 
AHOD (Australian HIV Observational Database, Australia):  
Central coordination: M. Law*, K. Petoumenos, R Puhr, R Huang (Sydney, New South 
Wales). Participating physicians (city, state): R. Moore, S. Edwards, J. Hoy, K. Watson, 
N. Roth, H Lau (Melbourne, Victoria); M Bloch, D. Baker, A. Carr, D. Cooper, (Sydney, 




Central coordination: G. Calvo, F. Torres, S. Mateu (Barcelona); 
Participating physicians (city): P. Domingo, M.A. Sambeat, J. Gatell, E. Del Cacho, J. 
Cadafalch, M. Fuster (Barcelona); C. Codina, G. Sirera, A. Vaqué (Badalona). 
 
The Brussels St Pierre Cohort (Belgium):  
Coordination: S. De Wit*, N. Clumeck, M. Delforge, C. Necsoi.  
Participating physicians: N. Clumeck, S. De Wit*, AF Gennotte, M. Gerard, K. Kabeya, 
D. Konopnicki, A. Libois, C. Martin, M.C. Payen, P. Semaille, Y. Van Laethem. 
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 CPCRA (USA): 
Central coordination: J. Neaton, G. Bartsch, W.M. El-Sadr*, E. Krum, G. Thompson, D. 
Wentworth; 
Participating physicians (city, state): R. Luskin-Hawk (Chicago, Illinois); E. Telzak 
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California); D. Cohn (Denver, Colorado); N. Markowitz (Detroit, Michigan); R. Arduino 
(Houston, Texas); D. Mushatt (New Orleans, Louisiana); G. Friedland (New Haven, 
Connecticut); G. Perez (Newark, New Jersey); E. Tedaldi (Philadelphia, Pennsylvania); 
E. Fisher (Richmond, Virginia); F. Gordin (Washington, DC); L.R. Crane (Detroit, 
Michigan); J. Sampson (Portland, Oregon); J. Baxter (Camden, New Jersey). 
 
EuroSIDA (multinational) 
Steering Committee: J Gatell, B Gazzard, A Horban, I Karpov, M Losso, A d’Arminio 
Monforte*, C Pedersen, M Ristola, A Phillips*, P Reiss*, JD Lundgren*, J Rockstroh 
Chair: J Rockstroh 
Study Co-leads: A Mocroft*, O Kirk* 
Coordinating Centre Staff: O Kirk*, L Peters, C Matthews, AH Fischer, A Bojesen, D 
Raben, D Kristensen, K Grønborg Laut, JF Larsen, D Podlekareva 
Statistical Staff: A Mocroft*, A Phillips*, A Cozzi-Lepri, L Shepherd, A Schultze, S 
Amele 
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The multi-centre study group, EuroSIDA (national coordinators in parenthesis). 
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires.  
Austria: (B Schmied), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, 
Medical University Innsbruck, Innsbruck.  
Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM 
Mitsura, Gomel State Medical University, Gomel; D Paduto, Regional AIDS Centre, 
Svetlogorsk.  
Belgium: (N Clumeck), S De Wit*, M Delforge, Saint-Pierre Hospital, Brussels; E 
Florence, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University 
Ziekenhuis Gent, Gent.  
Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, 
Sarajevo.  
Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb.  
Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, 
Charles University Hospital, Plzen.  
Denmark: G Kronborg, T Benfield, Hvidovre Hospital, Copenhagen; J Gerstoft, T 
Katzenstein, Rigshospitalet, Copenhagen; NF Møller, C Pedersen, Odense University 
Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus, L Wiese, Roskilde Hospital, 
Roskilde; L N Nielsen, Hillerod Hospital, Hillerod.  
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, 
Nakkusosakond Siseklinik, Kohtla-Järve.  
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Finland: (M Ristola), I Aho, Helsinki University Central Hospital, Helsinki.  
France: (JP Viard), Hôtel-Dieu, Paris; P-M Girard, Hospital Saint-Antoine, Paris; C 
Pradier*, E Fontas, Hôpital de l'Archet, Nice; C Duvivier, Hôpital Necker-Enfants 
Malades, Paris. 
Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule 
Hannover; O Degen, University Medical Center Hamburg-Eppendorf, Infectious 
Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; C Stefan, JW 
Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. 
Fätkenheuer, Universität Köln, Cologne.  
Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical Immunology Research 
Center, Tbilisi 
Greece: (P Gargalianos), G Xylomenos, K Armenis, Athens General Hospital "G 
Gennimatas"; H Sambatakou, Ippokration General Hospital, Athens. 
Hungary: (J Szlávik), Szent Lásló Hospital, Budapest. 
Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik.  
Ireland: (F Mulcahy), St. James's Hospital, Dublin. 
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; E Shahar, G Hassoun, 
Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah University Hospital, 
Jerusalem; D Elbirt, ZM Sthoeger, AIDS Center (Neve Or), Jerusalem. 
Italy: (A D’Arminio Monforte*), Istituto Di Clinica Malattie Infettive e Tropicale, Milan; 
R Esposito, I Mazeu, C Mussini, Università Modena, Modena; F Mazzotta, A Gabbuti, 
Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la 
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Sapienza, Rome; M Zaccarelli, A Antinori, R Acinapura, M Plazzi, Istituto Nazionale 
Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, 
Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan. 
Latvia: (B Rozentale), Infectology Centre of Latvia, Riga.  
Lithuania: (V Uzdaviniene) Vilnius University Hospital Santariskiu Klinikos, Vilnius; R 
Matulionyte, Center of Infectious Diseases, Vilnius University Hospital Santariskiu 
Klinikos, Vilnius.  
Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, Luxembourg.  
Netherlands: (P Reiss*), Academisch Medisch Centrum bij de Universiteit van 
Amsterdam, Amsterdam. 
Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo.  
Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A Horban, E 
Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak,  A Grzeszczuk, 
Medical University, Bialystok; M Parczewski, K Maciejewska, B Aksak-Was, Medical 
Univesity, Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, 
Chorzow; T Smiatacz, M Gensing, Medical University, Gdansk; E Jablonowska, E 
Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz; I Mozer-Lisewska, 
Poznan University of Medical Sciences, Poznan. 
Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas 
Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.  
Romania: (R Radoi), C Oprea, Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, 
Bucarest.  
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Russia: (A Panteleev), O Panteleev, St Petersburg AIDS Centre, St Peterburg; A 
Yakovlev, Medical Academy Botkin Hospital, St Petersburg; T Trofimora, Novgorod 
Centre for AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious 
Diseases, Kaliningrad; E Kuzovatova, Nizhny Novgorod Scientific and Research Institute 
of Epidemiology and Microbiology named after Academician I.N. Blokhina, Nizhny 
Novogrod; E Borodulina, E Vdoushkina, Samara State Medical University, Samara. 
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.  
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.  
Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona, Barcelona; S 
Moreno, J. M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, 
C Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M 
Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital 
Universitario de Alava, Vitoria-Gasteiz.  
Sweden:  (K Falconer), A Thalme, A Sonnerborg, Karolinska University Hospital, 
Stockholm; A Blaxhult, Venhälsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö 
University Hospital, Malmö. 
Switzerland: (A Scherrer), R Weber*, University Hospital Zurich; M Cavassini, 
University Hospital Lausanne; A Calmy, University Hospital Geneva; H Furrer, 
University Hospital Bern; M Battegay, University Hospital Basel; P Schmid, Cantonal 
Hospital St. Gallen. 
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Ukraine:  A Kuznetsova, Kharkov State Medical University, Kharkov; G Kyselyova, 
Crimean Republican AIDS centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS 
Prevention and Control CTR, Lviv. 
United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea and Westminster Hospital, 
London; AM Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A 
Phillips*, MA Johnson, A Mocroft*, Royal Free and University College Medical School, 
London (Royal Free Campus); C Orkin, Royal London Hospital, London; J Weber, G 
Scullard, Imperial College School of Medicine at St. Mary's, London; A Clarke, Royal 
Sussex County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh. 
The following centers have previously contributed data to EuroSIDA: 
Infectious Diseases Hospital, Sofia, Bulgaria 
Hôpital de la Croix Rousse, Lyon, France 
Hôpital de la Pitié-Salpétière, Paris, France 
Unité INSERM, Bordeaux, France 
Hôpital Edouard Herriot, Lyon, France 
Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany 
1st I.K.A Hospital of Athens, Athens, Greece 
Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy 
Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy 
Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, Italy 
Dérer Hospital, Bratislava, Slovakia 
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Hospital Carlos III, Departamento de Enfermedades Infecciosas, Madrid, Spain 
Kiev Centre for AIDS, Kiev, Ukraine 
Luhansk State Medical University, Luhansk, Ukraine 
Odessa Region AIDS Center, Odessa, Ukraine                                                                                                   
 
HivBivus (Sweden): 
Central coordination: L. Morfeldt, G. Thulin, A. Sundström. 
Participating physicians (city): B. Åkerlund (Huddinge); K. Koppel, A. Karlsson 
(Stockholm); L. Flamholc, C. Håkangård (Malmö). 
 
The ICONA Foundation (Italy): 
BOARD OF DIRECTORS 
A d’Arminio Monforte* (President), A Antinori, A Castagna, F Castelli, R Cauda, G Di 
Perri, M Galli, R Iardino, G Ippolito, GC Marchetti, CF Perno, F von Schloesser, P Viale  
SCIENTIFIC SECRETARY 
A d’Arminio Monforte*, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-
Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti 
STEERING COMMITTEE  
M Andreoni, A Ammassari, A Antinori, C Balotta, A Bandera, P Bonfanti, S Bonora, M 
Borderi, A Calcagno, L Calza, MR Capobianchi, A Castagna, F Ceccherini-Silberstein, A 
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Cingolani, P Cinque, A Cozzi-Lepri, A d’Arminio Monforte, A De Luca, A Di Biagio, E 
Girardi, N Gianotti, A Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo Caputo, G 
Madeddu, F Maggiolo, G Marchetti, S Marcotullio, L Monno, C Mussini, S Nozza, M 
Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, M Zaccarelli. 
STATISTICAL AND MONITORING TEAM 
A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M Shanyinde, A Tavelli 
BIOLOGICAL BANK INMI  
F Carletti, S Carrara, A Di Caro, S Graziano, F Petrone, G Prota, S Quartu, S Truffa 
PARTICIPATING PHYSICIANS AND CENTERS 
Italy A Giacometti, A Costantini, V Barocci (Ancona); G Angarano, L Monno, C Santoro 
(Bari); F  Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); F 
Castelli, C Minardi, E Quiros Roldan (Brescia); T Quirino, C Abeli (Busto Arsizio); PE  
Manconi, P Piano (Cagliari); B Cacopardo, B Celesia (Catania);  J Vecchiet, K Falasca 
(Chieti); A Pan, S Lorenzotti (Cremona); L Sighinolfi, D Segala (Ferrara); F Mazzotta, F 
Vichi (Firenze); G Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazzarello 
(Genova); C Mastroianni, V Belvisi (Latina); P Bonfanti, I Caramma (Lecco); A 
Chiodera, P Milini (Macerata); A d’Arminio Monforte, M Galli, A Lazzarin, G 
Rizzardini, M Puoti, A Castagna, G Marchetti, MC Moioli, R Piolini, AL Ridolfo, S 
Salpietro, C Tincati, (Milano); C Mussini, C Puzzolante (Modena); A Gori, G Lapadula 
(Monza); N Abrescia, A Chirianni, G Borgia, R Orlando, G Bonadies, F Di Martino, I 
Gentile, L Maddaloni (Napoli); AM Cattelan, S Marinello (Padova); A Cascio, C 
Colomba (Palermo); F Baldelli, E Schiaroli (Perugia);  G  Parruti, F Sozio (Pescara); G 
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Magnani, MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R Cauda, A Cristaudo, 
V Vullo, R Acinapura, G Baldin, M Capozzi, S Cicalini, A Cingolani, L Fontanelli 
Sulekova, G Iaiani, A Latini, I Mastrorosa, MM Plazzi, S Savinelli, A Vergori (Roma); 
M Cecchetto, F Viviani (Rovigo); G Madeddu, P Bagella (Sassari); A De Luca, B 
Rossetti (Siena);  A Franco, R Fontana Del Vecchio (Siracusa); D Francisci, C Di Giuli 
(Terni); P Caramello, G Di Perri, S Bonora, GC Orofino, M Sciandra (Torino); M 
Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza) G Starnini, A 
Ialungo(Viterbo). 
 
Nice HIV Cohort (France):  
Central coordination: C. Pradier*, E. Fontas, K. Dollet, C. Caissotti.  
Participating physicians: P. Dellamonica, E. Bernard, J. Courjon, E. Cua, F. De Salvador-
Guillouet, J.Durant, C. Etienne, S. Ferrando, V. Mondain-Miton, A. Naqvi, I. Perbost,S. 
Pillet , B. Prouvost-Keller, P. Pugliese, V. Rio, K. Risso, P.M. Roger. 
  
SHCS (Swiss HIV Cohort Study, Switzerland): 
The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals,15 
affiliated hospitals and 36 private physicians (listed in http://www.shcs.ch/180-health-
care-providers). 
Members of the Swiss HIV Cohort Study : 
Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini 
M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the 
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Clinical and Laboratory Committee), Fux CA, Günthard HF (President of the SHCS), 
Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, 
Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, 
Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, 
Pantaleo G, Paioni P, Rauch A (Chairman of the Scientific Board), Rudin C (Chairman of 
the Mother & Child Substudy), Scherrer AU (Head of Data Centre), Schmid P, Speck R, 
Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R*, Yerly S. 
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Table 1: Univariate associations between ABC exposure and established CVD risk 
factors and subsequent myocardial infarction 
 
Factor RR 95% CI p-value 
Cumulative exposure to ABC (/5 years) 0.86 (0.68, 1.10) 0.23 
On ABC at time of MI 0.90 (0.63, 1.29) 0.58 
Recent use of ABC 1.19 (0.82, 1.71) 0.36 
Calendar year (time-updated) 1999-2001 7.73 (3.36, 17.79) 0.0001 
 2002-2004 3.28 (1.79, 6.02) 0.0001 
 2005-2007 2.25 (1.25, 4.04) 0.0001 
 2008-2010 1.54 (0.86, 2.76) 0.15 
 2011-2013 1.01 (0.55, 1.85) 0.97 
 2014-2016 1 - - 
Gender Male 0.85 (0.47, 1.54) 0.59 
 Female 1 - - 
Age (/5 years older) 1.01 (0.99, 1.03) 0.19 
Smoking status Current 1.07 (0.59, 1.95) 0.82 
 Ex- 1.25 (0.69, 2.29) 0.47 
 Never 1 - - 
 Unknown 1.04 (0.42, 2.61) 0.93 
Ethnic group White 1 - - 
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 Non-white 0.86 (0.62, 1.21) 0.40 
Mode of acquisition MSM 1 - - 
 IDU 0.66 (0.36, 1.20) 0.17 
 Heterosexual 1.03 (0.68, 1.56) 0.89 
 Other/unknown 2.25 (1.25, 4.04) 0.007 
Dyslipidaemia1 0.68 (0.40, 1.16) 0.16 
BMI <18 1.14 (0.50, 2.60) 0.76 
 >18, <26 1 - - 
 >26, <30 0.90 (0.57, 1.44) 0.67 
 >30 1.01 (0.49, 2.09) 0.97 
 Not known 2.29 (1.19, 4.40) 0.01 
Diabetes 1.70 (1.15, 2.51) 0.008 
Hypertension2 0.74 (0.48, 1.16) 0.19 
Cumulative exposure to lopinavir (/5 years) 0.84 (0.58, 1.21) 0.35 
Cumulative exposure to indinavir (/5 years) 1.21 (0.81, 1.80) 0.35 
Cumulative exposure to darunavir (/5 years) 0.61 (0.29, 1.29) 0.20 
1Total cholesterol >6.2 mmol/l, HDL cholesterol <0.9 mmol/l, triglyceride >2.3 mmol/l 
or receipt of lipid-lowering medication; 2Systolic blood pressure >140 mmHg, diastolic 
blood pressure >90 mmHg or receipt of anti-hypertensive or ACE inhibitor medication; 
MI: myocardial infarction; ABC: abacavir; RR: relative rate; CI: confidence interval; 
MSM: men who have sex with men; IDU: injection drug users; BMI: body mass index. 
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